Valuation: Kamada Ltd.

Market Cap 1.23B 412M 362M 333M 312M 585M 38.87B 595M 4B 1.55B 19.16B 1.55B 1.51B 66.59B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.23B 412M 362M 333M 312M 585M 38.87B 595M 4B 1.55B 19.16B 1.55B 1.51B 66.59B EV / Sales 2026 *
2.1x
EV / Sales 2027 * 1.91x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 2015-06-30
Director of Finance/CFO 55 2017-12-30
Chief Operating Officer 53 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Change 5-day change 1-year change 3-year change Capi.($)
+3.07%+4.32% - - 412M
-0.53%+1.67%+19.19%-20.47% 63.09B
-0.19%+2.52%+51.66%+216.28% 55.61B
+0.07%+38.60%+38.60%+38.60% 41.64B
-2.36%-1.25%-52.13%-58.98% 38.98B
+1.19%+2.74%+58.64%-29.02% 29.82B
-1.11%-6.58%+122.45%-49.58% 23.71B
-0.86%+9.48%+59.19%+72.19% 21.48B
-1.25%-0.27%-4.39%+142.42% 16.87B
-1.94%+3.73%+65.97%+121.83% 16.74B
Average -0.40%+2.98%+39.91%+48.14% 34.22B
Weighted average by Cap. -0.64%+2.91%+34.46%+45.45%

Financials

2026 *2027 *
Net sales 585M 196M 172M 159M 148M 278M 18.5B 283M 1.9B 737M 9.12B 736M 720M 31.69B 642M 215M 189M 174M 163M 305M 20.31B 311M 2.09B 809M 10.01B 808M 790M 34.79B
Net income 72.01M 24.14M 21.21M 19.54M 18.27M 34.27M 2.28B 34.9M 234M 90.81M 1.12B 90.67M 88.68M 3.9B 104M 34.75M 30.52M 28.12M 26.3M 49.32M 3.28B 50.22M 337M 131M 1.62B 130M 128M 5.62B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-